Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.45 |
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | PPARD | Q03181 | 9/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992982 | 0.85 | PPARA (0.55) | PPARAPPARGPPARD | |
| SCHEMBL4076321 | 0.84 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL4073462 | 0.80 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL3965062 | 0.80 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL3963764 | 0.80 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL3962800 | 0.80 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL3968805 | 0.78 | PPARA (0.48) | PPARAPPARGPPARD | |
| SCHEMBL5721779 | 0.76 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL5721599 | 0.76 | PPARA (0.49) | PPARAPPARGPPARDGPR34 | |
| SCHEMBL5979437 | 0.75 | PPARA (0.48) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885PPARD 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.